<DOC>
	<DOC>NCT01912443</DOC>
	<brief_summary>To assess the safety profile of bevacizumab in combination with chemotherapy for the treatment of metastatic colorectal cancer</brief_summary>
	<brief_title>Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This is a multi-centre, observational, non-interventional study. Patients with metastatic colorectal cancer eligible for Bevacizumab in combination with chemotherapy treatment will be enrolled in this trial.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>with histologically confirmed metastatic colorectal cancer patients with metastatic colorectal cancer who are eligible for Bevacizumab in combination with chemotherapy treatment Written informed consent Unlimited line of treatment (firstline or second line is not limited) Patients who are not eligible for Bevacizumab treatment according to locally approved Bevacizumab China package insert will be excluded. The following patients are not eligible for Bevacizumab treatment according to local Bevacizumab China package insert: Recent history of serious hemorrhage or hemoptysis of ≥1/2 teaspoon of red blood Proteinuria at baseline: Patients discovered to have ≥ 2 grams of proteinuria/24 hours * The measurement of 24hour proteinuria level is recommended for patients with moderate to high proteinuria risk indicated by clinical judgement. The treatment with bevacizumab should be delayed when proteinuria is ≥2g/24 hours. Major surgical procedure within 28 days prior to treatment initiation, or not fully healed wounds Pregnant or lactating women Excluding patients known to be allergic to bevacizumab or any of the excipients</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>